DETERMINATION OF PROGNOSTIC AND PREDICTIVE VALUES OF CLINICAL AND HISTOPATHOLOGIC FEATURES, AND EXPRESSION OF XPC, MSH2 AND RAD51 IN PATIENTS DIAGNOSED WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH CISPLATIN-VINORELBINE

• Grant number: 10/16134-8
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: December 01, 2010
• End date: May 31, 2011
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Gilberto de Castro Junior
• Grantee: Fernando José Bigaton
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Lung cancer is strongly associated with smoking habits and it is ranked as the first cause of cancer-related deaths worldwide, being non-small cell (NSCLC) the most frequent histological type.The standard treatment for advanced NSCLC is the combination of a platinum compound with a third generation cytotoxic agent such as vinorelbine, gemcitabine, paclitaxel, docetaxel and pemetrexed. This chemotherapy offers a modest gain in survival and better quality of life in those patients presenting with performance status ECOG 0-1, compared with best supportive care alone. In order to contribute to a better selection of patients eligible for systemic chemotherapy, here we will study the prognostic and predictive values of clinical and histopathological features in patients with advanced NSCLC treated with cisplatin and vinorelbine, as well as the role of the expression of biological markers related to DNA repair (XPC, RAD51 and MSH2).